Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma

Tamotsu Kita, Kunihiko Yokoyama, Takahiro Higuchi, Seigo Kinuya, Junichi Taki, Kenichi Nakajima, Takatoshi Michigishi, Norihisa Tonami

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objective: This study was performed to clarify factors that might influence short-term side effects occurring within 96 hours after administration of 131I for patients with thyroid carcinoma. Methods: In 71 patients with differentiated thyroid carcinoma, short-term side effects including gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache were retrospectively analyzed. All patients were given domperidone for prevention of gastrointestinal complaints and advised to consume sour foods to promote discharge of radioiodine from the salivary glands. Selected factors possibly affecting the incidence of side effects were dose per body weight, TSH, effective half-life of 131I, sex, age, 131I accumulation into the stomach and salivary glands, and edema prior to radioiodine administration. The factors were evaluated by multivariate analyses. Results: Incidence of gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache was 65.2%, 50.0%, 9.8% and 4.4%, respectively. In gastrointestinal complaints, the incidence of appetite loss, nausea and vomiting was 60.9%, 40.2% and 7.6%, respectively. The gastrointestinal complaints increased significantly in the patients dosed above 55.5 MBq/kg and with TSH elevation. For salivary gland swelling with pain, female patients displayed a significantly higher incidence than males. No statistically significant factors were detected for change in taste or headache. Conclusions: Significant factors influencing short-term side effects were dose per body weight and TSH values for gastrointestinal complaints, and female sex for salivary gland swelling with pain. Our preliminary experience suggests that the most frequent gastrointestinal complaints can be prevented with ramosetron.

Original languageEnglish
Pages (from-to)345-349
Number of pages5
JournalAnnals of nuclear medicine
Volume18
Issue number4
DOIs
Publication statusPublished - Jun 2004
Externally publishedYes

Fingerprint

Salivary Glands
Thyroid Neoplasms
Headache
Pain
Incidence
Therapeutics
Body Weight
Domperidone
Appetite
Nausea
Vomiting
Half-Life
Edema
Stomach
Multivariate Analysis
Food

Keywords

  • Dose
  • Radioiodine therapy
  • Short-term side effects
  • Thyroid cancer
  • TSH

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. / Kita, Tamotsu; Yokoyama, Kunihiko; Higuchi, Takahiro; Kinuya, Seigo; Taki, Junichi; Nakajima, Kenichi; Michigishi, Takatoshi; Tonami, Norihisa.

In: Annals of nuclear medicine, Vol. 18, No. 4, 06.2004, p. 345-349.

Research output: Contribution to journalArticle

Kita, Tamotsu ; Yokoyama, Kunihiko ; Higuchi, Takahiro ; Kinuya, Seigo ; Taki, Junichi ; Nakajima, Kenichi ; Michigishi, Takatoshi ; Tonami, Norihisa. / Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. In: Annals of nuclear medicine. 2004 ; Vol. 18, No. 4. pp. 345-349.
@article{19014e5a4003478cbe8fcb349fa63e19,
title = "Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma",
abstract = "Objective: This study was performed to clarify factors that might influence short-term side effects occurring within 96 hours after administration of 131I for patients with thyroid carcinoma. Methods: In 71 patients with differentiated thyroid carcinoma, short-term side effects including gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache were retrospectively analyzed. All patients were given domperidone for prevention of gastrointestinal complaints and advised to consume sour foods to promote discharge of radioiodine from the salivary glands. Selected factors possibly affecting the incidence of side effects were dose per body weight, TSH, effective half-life of 131I, sex, age, 131I accumulation into the stomach and salivary glands, and edema prior to radioiodine administration. The factors were evaluated by multivariate analyses. Results: Incidence of gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache was 65.2{\%}, 50.0{\%}, 9.8{\%} and 4.4{\%}, respectively. In gastrointestinal complaints, the incidence of appetite loss, nausea and vomiting was 60.9{\%}, 40.2{\%} and 7.6{\%}, respectively. The gastrointestinal complaints increased significantly in the patients dosed above 55.5 MBq/kg and with TSH elevation. For salivary gland swelling with pain, female patients displayed a significantly higher incidence than males. No statistically significant factors were detected for change in taste or headache. Conclusions: Significant factors influencing short-term side effects were dose per body weight and TSH values for gastrointestinal complaints, and female sex for salivary gland swelling with pain. Our preliminary experience suggests that the most frequent gastrointestinal complaints can be prevented with ramosetron.",
keywords = "Dose, Radioiodine therapy, Short-term side effects, Thyroid cancer, TSH",
author = "Tamotsu Kita and Kunihiko Yokoyama and Takahiro Higuchi and Seigo Kinuya and Junichi Taki and Kenichi Nakajima and Takatoshi Michigishi and Norihisa Tonami",
year = "2004",
month = "6",
doi = "10.1007/BF02984474",
language = "English",
volume = "18",
pages = "345--349",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma

AU - Kita, Tamotsu

AU - Yokoyama, Kunihiko

AU - Higuchi, Takahiro

AU - Kinuya, Seigo

AU - Taki, Junichi

AU - Nakajima, Kenichi

AU - Michigishi, Takatoshi

AU - Tonami, Norihisa

PY - 2004/6

Y1 - 2004/6

N2 - Objective: This study was performed to clarify factors that might influence short-term side effects occurring within 96 hours after administration of 131I for patients with thyroid carcinoma. Methods: In 71 patients with differentiated thyroid carcinoma, short-term side effects including gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache were retrospectively analyzed. All patients were given domperidone for prevention of gastrointestinal complaints and advised to consume sour foods to promote discharge of radioiodine from the salivary glands. Selected factors possibly affecting the incidence of side effects were dose per body weight, TSH, effective half-life of 131I, sex, age, 131I accumulation into the stomach and salivary glands, and edema prior to radioiodine administration. The factors were evaluated by multivariate analyses. Results: Incidence of gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache was 65.2%, 50.0%, 9.8% and 4.4%, respectively. In gastrointestinal complaints, the incidence of appetite loss, nausea and vomiting was 60.9%, 40.2% and 7.6%, respectively. The gastrointestinal complaints increased significantly in the patients dosed above 55.5 MBq/kg and with TSH elevation. For salivary gland swelling with pain, female patients displayed a significantly higher incidence than males. No statistically significant factors were detected for change in taste or headache. Conclusions: Significant factors influencing short-term side effects were dose per body weight and TSH values for gastrointestinal complaints, and female sex for salivary gland swelling with pain. Our preliminary experience suggests that the most frequent gastrointestinal complaints can be prevented with ramosetron.

AB - Objective: This study was performed to clarify factors that might influence short-term side effects occurring within 96 hours after administration of 131I for patients with thyroid carcinoma. Methods: In 71 patients with differentiated thyroid carcinoma, short-term side effects including gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache were retrospectively analyzed. All patients were given domperidone for prevention of gastrointestinal complaints and advised to consume sour foods to promote discharge of radioiodine from the salivary glands. Selected factors possibly affecting the incidence of side effects were dose per body weight, TSH, effective half-life of 131I, sex, age, 131I accumulation into the stomach and salivary glands, and edema prior to radioiodine administration. The factors were evaluated by multivariate analyses. Results: Incidence of gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache was 65.2%, 50.0%, 9.8% and 4.4%, respectively. In gastrointestinal complaints, the incidence of appetite loss, nausea and vomiting was 60.9%, 40.2% and 7.6%, respectively. The gastrointestinal complaints increased significantly in the patients dosed above 55.5 MBq/kg and with TSH elevation. For salivary gland swelling with pain, female patients displayed a significantly higher incidence than males. No statistically significant factors were detected for change in taste or headache. Conclusions: Significant factors influencing short-term side effects were dose per body weight and TSH values for gastrointestinal complaints, and female sex for salivary gland swelling with pain. Our preliminary experience suggests that the most frequent gastrointestinal complaints can be prevented with ramosetron.

KW - Dose

KW - Radioiodine therapy

KW - Short-term side effects

KW - Thyroid cancer

KW - TSH

UR - http://www.scopus.com/inward/record.url?scp=4143103463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143103463&partnerID=8YFLogxK

U2 - 10.1007/BF02984474

DO - 10.1007/BF02984474

M3 - Article

C2 - 15359929

AN - SCOPUS:4143103463

VL - 18

SP - 345

EP - 349

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 4

ER -